Biofrontera

BFRIW · NASDAQ

$0.005+$0.00 (+0.00%)TodayMarket closed · Oct 23, 7:52 PM ET

Prev close $0.005

Latest news

Press releaseOct 8, 9:22 AM ETGlobe Newswire
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
Press releaseSep 14, 9:26 AM ETGlobe Newswire
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Press releaseAug 13, 8:51 AM ETGlobe Newswire
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
Press releaseMay 14, 7:30 AM ETGlobe Newswire
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
Press releaseMay 8, 4:00 PM ETGlobe Newswire
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
Press releaseMar 19, 9:25 AM ETGlobe Newswire
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Press releaseMar 9, 5:25 PM ETGlobe Newswire
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
Press releaseMar 9, 9:15 AM ETGlobe Newswire
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
Press releaseFeb 26, 9:15 AM ETGlobe Newswire
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable
Press releaseFeb 17, 9:15 AM ETGlobe Newswire
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities
Press releaseJan 8, 8:45 AM ETGlobe Newswire
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones
Press releaseNov 22, 9:10 AM ETGlobe Newswire
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update

Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026

Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note